Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) EV/EBITDA Ratio: 20.92x

Is Agilent Technologies, Inc.’s EV/EBITDA ratio high or low?

Agilent Technologies, Inc.'s EV/EBITDA ratio of 20.92x is in line with its 5-year average of 23.11x, near the low end of its 5-year range (16.58x–37.96x).

The EV/EBITDA ratio for Agilent Technologies, Inc. (A) is 20.92x as of Wednesday, June 10, 2026. It is below its 12-month average by 0.94% (21.12x).

A EV/EBITDA Ratio Chart

A EV/EBITDA Ratio
20.92x+1.21% 1Y
Zoom

A Average EV/EBITDA Ratio Chart

A Current vs Average EV/EBITDA Ratio Chart

A EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

20.92x

EV/EBITDA RATIO AVG TTM

21.12x

EV/EBITDA RATIO AVG 3Y

21.69x

EV/EBITDA RATIO AVG 5Y

23.11x

EV/EBITDA RATIO AVG 10Y

22.16x

EV/EBITDA RATIO AVG 15Y

19.36x

EV/EBITDA RATIO AVG 20Y

18.01x

CURRENT VS TTM AVG

-0.94%

CURRENT VS 3Y AVG

-3.57%

CURRENT VS 5Y AVG

-9.49%

CURRENT VS 10Y AVG

-5.59%

CURRENT VS 15Y AVG

+8.06%

CURRENT VS 20Y AVG

+16.17%

A Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Agilent Technologies, Inc. (A)$37.17B20.92x21.12x21.69x23.11x
Zoetis Inc. (ZTS)$34.20B10.33x15.67x20.68x23.76x
Centene Corporation (CNC)$31.94BN/A4.99x7.28x9.49x
Medline Inc. (MDLN)$30.90B13.75x15.00x15.00x15.00x
IQVIA Holdings Inc. (IQV)$30.60B8.90x13.19x14.98x17.09x
Humana Inc. (HUM)$43.78B18.61x11.68x11.33x12.36x
IDEXX Laboratories, Inc. (IDXX)$44.47B30.48x35.75x34.46x38.26x
DexCom, Inc. (DXCM)$29.24B23.24x28.10x43.48x70.03x
Biogen Inc. (BIIB)$29.00B11.60x8.56x11.16x12.22x
Veeva Systems Inc. (VEEV)$26.73B25.37x43.29x56.90x62.37x

EV/EBITDA vs. its own history

At 20.9, EV/EBITDA is richer than usual — richer than 70% of its 20-year range.

20-year low

3.4

median

18.5

20-year high

38.0

cheaperricher

Understanding EV/EBITDA

Enterprise Value (EV) = Market Cap + Total Debt - Cash

EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization

EV/EBITDA is commonly used for comparing companies because:

  • It accounts for debt levels (capital structure neutral)
  • It removes effects of different depreciation policies
  • It can be compared across countries with different tax rates
  • It can remain available when net income is negative, if EBITDA is positive

Agilent Technologies, Inc. EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Agilent Technologies, Inc. EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The EV/EBITDA ratio for A stock is 20.92x.
Is Agilent Technologies, Inc.'s EV/EBITDA ratio high or low?
Agilent Technologies, Inc.'s EV/EBITDA ratio of 20.92x is in line with its 5-year average of 23.11x, near the low end of its 5-year range (16.58x–37.96x).
What is the TTM average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The TTM average EV/EBITDA ratio for A stock is 21.12x.
What is the 3Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The 3Y average EV/EBITDA ratio for A stock is 21.69x.
What is the 5Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The 5Y average EV/EBITDA ratio for A stock is 23.11x.
What is the 10Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The 10Y average EV/EBITDA ratio for A stock is 22.16x.
What is the 15Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The 15Y average EV/EBITDA ratio for A stock is 19.36x.
What is the 20Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
The 20Y average EV/EBITDA ratio for A stock is 18.01x.

Agilent Technologies, Inc. EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-1020.92x
2026-06-0921.51x
2026-06-0821.08x
2026-06-0521.50x
2026-06-0421.95x
2026-06-0321.80x
2026-06-0221.44x
2026-06-0121.58x
2026-05-2921.98x
2026-05-2821.95x
2026-05-2718.91x
2026-05-2618.79x
2026-05-2218.77x
2026-05-2118.75x
2026-05-2018.59x
2026-05-1918.09x
2026-05-1818.33x
2026-05-1518.27x
2026-05-1418.51x
2026-05-1318.43x
2026-05-1218.45x
2026-05-1118.23x
2026-05-0818.88x
2026-05-0719.35x
2026-05-0619.20x
2026-05-0519.17x
2026-05-0418.34x
2026-05-0118.71x
2026-04-3018.87x
2026-04-2918.20x
2026-04-2818.76x
2026-04-2718.88x
2026-04-2418.87x
2026-04-2318.69x
2026-04-2219.63x
2026-04-2119.88x
2026-04-2019.71x
2026-04-1719.85x
2026-04-1619.29x
2026-04-1519.52x
2026-04-1419.62x
2026-04-1319.17x
2026-04-1018.79x
2026-04-0918.84x
2026-04-0819.08x
2026-04-0718.61x
2026-04-0618.76x
2026-04-0218.86x
2026-04-0118.71x
2026-03-3118.62x
2026-03-3018.32x
2026-03-2718.04x
2026-03-2618.54x
2026-03-2518.47x
2026-03-2418.66x
2026-03-2318.32x
2026-03-2018.20x
2026-03-1918.27x
2026-03-1818.24x
2026-03-1718.43x
2026-03-1618.29x
2026-03-1318.24x
2026-03-1218.26x
2026-03-1118.85x
2026-03-1018.85x
2026-03-0919.04x
2026-03-0618.79x
2026-03-0519.26x
2026-03-0419.64x
2026-03-0319.41x
2026-03-0219.14x
2026-02-2719.64x
2026-02-2619.58x
2026-02-2520.16x
2026-02-2420.11x
2026-02-2320.08x
2026-02-2019.87x
2026-02-1920.41x
2026-02-1820.50x
2026-02-1720.02x
2026-02-1320.32x
2026-02-1220.18x
2026-02-1120.80x
2026-02-1020.82x
2026-02-0920.59x
2026-02-0620.91x
2026-02-0520.92x
2026-02-0421.43x
2026-02-0321.30x
2026-02-0221.81x
2026-01-3021.57x
2026-01-2921.48x
2026-01-2821.57x
2026-01-2721.89x
2026-01-2621.85x
2026-01-2321.75x
2026-01-2222.31x
2026-01-2122.48x
2026-01-2021.88x
2026-01-1622.46x
2026-01-1523.27x
2026-01-1423.44x
2026-01-1323.50x
2026-01-1223.76x
2026-01-0923.84x
2026-01-0823.41x
2026-01-0723.73x
2026-01-0623.70x
2026-01-0522.97x
2026-01-0222.20x
2025-12-3121.91x
2025-12-3022.15x
2025-12-2922.20x
2025-12-2622.27x
2025-12-2422.26x
2025-12-2322.27x
2025-12-2222.29x
2025-12-1922.09x
2025-12-1822.75x
2025-12-1722.72x
2025-12-1623.12x
2025-12-1523.34x
2025-12-1223.20x
2025-12-1123.70x
2025-12-1023.80x
2025-12-0923.35x
2025-12-0823.63x
2025-12-0524.12x
2025-12-0424.57x
2025-12-0324.72x
2025-12-0224.64x
2025-12-0124.85x
2025-11-2825.39x
2025-11-2625.53x
2025-11-2525.97x
2025-11-2425.40x
2025-11-2125.03x
2025-11-2024.05x
2025-11-1923.94x
2025-11-1823.86x
2025-11-1723.96x
2025-11-1424.33x
2025-11-1324.34x
2025-11-1225.07x
2025-11-1124.74x
2025-11-1024.26x
2025-11-0724.32x
2025-11-0624.43x
2025-11-0524.32x
2025-11-0424.21x
2025-11-0323.99x
2025-10-3124.26x
2025-10-3023.78x
2025-10-2923.75x
2025-10-2824.17x
2025-10-2724.29x
2025-10-2424.52x
2025-10-2324.43x
2025-10-2224.18x
2025-10-2124.15x
2025-10-2023.72x
2025-10-1723.55x
2025-10-1623.42x
2025-10-1523.19x
2025-10-1422.94x
2025-10-1322.97x
2025-10-1022.71x
2025-10-0923.26x
2025-10-0823.37x
2025-10-0723.02x
2025-10-0623.50x
2025-10-0323.51x
2025-10-0223.04x
2025-10-0123.02x
2025-09-3021.40x
2025-09-2920.67x
2025-09-2620.61x
2025-09-2520.37x
2025-09-2420.77x
2025-09-2321.02x
2025-09-2221.08x
2025-09-1921.08x
2025-09-1821.28x
2025-09-1721.14x
2025-09-1621.21x
2025-09-1520.97x
2025-09-1220.59x
2025-09-1121.14x
2025-09-1020.73x
2025-09-0921.07x
2025-09-0821.36x
2025-09-0521.46x
2025-09-0421.42x
2025-09-0320.90x
2025-09-0220.90x
2025-08-2920.97x
2025-08-2821.39x
2025-08-2720.37x
2025-08-2620.31x
2025-08-2520.45x
2025-08-2220.85x
2025-08-2120.12x
2025-08-2020.44x
2025-08-1920.60x
2025-08-1820.29x
2025-08-1520.46x
2025-08-1420.40x
2025-08-1320.63x
2025-08-1220.15x
2025-08-1119.63x
2025-08-0819.71x
2025-08-0719.61x
2025-08-0619.49x
2025-08-0519.76x
2025-08-0419.75x
2025-08-0119.53x
2025-07-3119.74x
2025-07-3020.27x
2025-07-2920.56x
2025-07-2820.51x
2025-07-2520.61x
2025-07-2420.64x
2025-07-2320.50x
2025-07-2219.97x
2025-07-2119.30x
2025-07-1819.61x
2025-07-1720.00x
2025-07-1619.52x
2025-07-1519.44x
2025-07-1420.60x
2025-07-1121.12x
2025-07-1021.26x
2025-07-0920.80x
2025-07-0820.75x
2025-07-0720.46x
2025-07-0320.81x
2025-07-0220.69x
2025-07-0120.66x
2025-06-3020.26x
2025-06-2720.45x
2025-06-2620.49x
2025-06-2520.36x
2025-06-2420.20x
2025-06-2319.96x
2025-06-2019.87x
2025-06-1819.86x
2025-06-1719.95x
2025-06-1620.43x
2025-06-1320.11x
2025-06-1220.41x
2025-06-1120.54x
2025-06-1020.67x
2025-06-0920.06x
2025-06-0619.90x
2025-06-0519.60x
2025-06-0419.77x
2025-06-0319.41x
2025-06-0219.13x
2025-05-3019.28x
2025-05-2918.77x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell